Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177.
The pharmacokinetics and pharmacodynamic effect on platelet activation of a single 800 mg oral dose of BM 13.177 have been investigated in 8 male volunteers. BM 13.177 disappeared from plasma with a terminal elimination half-life of 0.85 h. 52% of the dose was excreted unchanged in urine. Assuming complete absorption, total clearance was calculated to be 741.3 ml/min and renal clearance to range from 310.4 to 396.9 ml/min. The pharmacodynamic studies were performed ex vivo/in vitro in studies were performed ex vivo/in vitro in platelets stimulated either with methyl mercury chloride or with U 46619. Methyl mercury chloride is a platelet activator that requires TXA2 formation from endogenous arachidonic acid, whereas U 46619 is a stable PGH2 analogue and thromboxane mimetic at the platelet TXA2/PGH2 receptor. A close correlation between the plasma concentration-time profile of BM 13.177 and inhibition of platelet shape change or aggregation was demonstrated.
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000648:ultrastructure; D005343:Fibrinolytic Agents / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008297:Male; D008767:Methylmercury Compounds / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology; D012701:Serotonin / Q000097:blood; D013449:Sulfonamides / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors
D005343:Fibrinolytic Agents; D008767:Methylmercury Compounds; D011450:Prostaglandin Endoperoxides, Synthetic; D013449:Sulfonamides; D012701:Serotonin; C040624:sulotroban; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C004925:methylmercuric chloride